Abstract
Purpose
To compare the clinical and ongoing pregnancy rates between a protocol using oral dydrogesterone with human menopausal gonadotropin (HMG) for progestin-primed ovarian stimulation (PPOS) and the typical gonadotropin-releasing hormone (GnRH) antagonist regimen in women undergoing controlled ovarian hyperstimulation (COH).
Methods
This was a prospective, controlled study of 251 women who underwent COH for in vitro fertilization between October 2016 and July 2017. The patients were allocated alternately into two groups: a dydrogesterone protocol (study group) and a GnRH antagonist protocol (control group). In study group, dydrogesterone (20 mg/day) plus HMG (150 or 225 IU) were administered simultaneously beginning on days 2 or 3 of the menstrual cycle. In both groups, all high-quality embryos were cryopreserved for later transfer. The primary outcome was the ongoing pregnancy rate at 12 weeks per frozen–thawed embryo transfer (FET) and the secondary outcome was the clinical pregnancy rate.
Results
None of the patients experienced a premature luteinizing hormone surge. During the follow-up period, 397 FET cycles were completed. The ongoing pregnancy rates at 12 weeks were 40.0% in study group versus 38.1% in control group (absolute difference 1.9%; 95% CI − 6.83 to 17.2%). The clinical pregnancy rate in study group (52.8%) was also not inferior to that in control group (49.5%; absolute difference 3.3%; 95% CI − 4.02 to 20.2%).
Conclusions
The clinical and ongoing pregnancy rates in study group were comparable to those in control group. Therefore, PPOS with dydrogesterone is a reasonable option to provide COH.
Similar content being viewed by others
Abbreviations
- AMH:
-
Anti-Müllerian hormone
- ART:
-
Assisted reproductive technology
- BMI:
-
Body mass index
- CI:
-
Confidence interval
- COCs:
-
Cumulus–oocyte complexes
- COH:
-
Controlled ovarian hyperstimulation
- E2:
-
Estradiol 2
- FET:
-
Frozen embryo transfer
- GnRH:
-
Gonadotropin-releasing hormone
- hCG:
-
Human chorionic gonadotropin
- HMG:
-
Human menopausal gonadotropin
- HRT:
-
Hormone replacement therapy
- IVF:
-
In vitro fertilization
- ICSI:
-
Intra-cytoplasmic sperm injection
- LH:
-
Luteinizing hormone
- OHSS:
-
Ovarian hyperstimulation syndrome
- P4:
-
Progesterone
- PPOS:
-
Progestin-primed ovarian stimulation
- SD:
-
Standard deviation
- USD:
-
United States dollar
References
Firouzabadi RD, Ahmadi S, Oskouian H, Davar R (2010) Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Arch Gynecol Obstet 281(1):81–85. https://doi.org/10.1007/s00404-009-1073-5
Mourad S, Brown J, Farquhar C (2017) Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev 1:CD012103. https://doi.org/10.1002/14651858.cd012103.pub2
Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ (2016) Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 4:CD001750. https://doi.org/10.1002/14651858.cd001750.pub4
Reichman DE, Zakarin L, Chao K, Meyer L, Davis OK, Rosenwaks Z (2014) Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertility Steril 102(1):99–102. https://doi.org/10.1016/j.fertnstert.2014.04.010
Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z (2015) Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertility Steril 104(1):62–70.e63. https://doi.org/10.1016/j.fertnstert.2015.03.022
Zhu X, Ye H, Fu Y (2016) The utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine (Baltimore) 95(28):e4193. https://doi.org/10.1097/md.0000000000004193
Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y (2016) Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine (Baltimore) 95(9):e2939. https://doi.org/10.1097/MD.0000000000002939
Zhu X, Ye H, Fu Y (2017) Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Steril 108(3):505–512. https://doi.org/10.1016/j.fertnstert.2017.06.017 (e502)
Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, Shoham Z (2014) Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen–thawed embryo transfer cycles. Fertility Steril 101(1):105–111. https://doi.org/10.1016/j.fertnstert.2013.09.007
Wang N, Wang Y, Chen Q, Dong J, Tian H, Fu Y, Ai A, Lyu Q, Kuang Y (2016) Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin Endocrinol (Oxf) 84(5):720–728. https://doi.org/10.1111/cen.12983
Kwik M, Maxwell E (2016) Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 28(4):236–241. https://doi.org/10.1097/gco.0000000000000284
Atkinson P, Koch J, Ledger WL (2014) GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates. Aust N Z J Obstet Gynaecol 54(6):581–585. https://doi.org/10.1111/ajo.12277
Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Quan X, Lyu Q, Kuang Y, Ai A (2018) New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod 33(2):229–237. https://doi.org/10.1093/humrep/dex367
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (2008) Classification and pharmacology of progestins. Maturitas 61(1–2):171–180
Schindler AE (2009) Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas 65(Suppl 1):S3–11. https://doi.org/10.1016/j.maturitas.2009.10.011
Nadarajah R, Rajesh H, Wong KY, Faisal F, Yu SL (2016) Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singap Med J. https://doi.org/10.11622/smedj.2016080
Cummins JM, Breen TM, Harrison KL, Shaw JM, Wilson LM, Hennessey JF (1986) A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. J In Vitro Fertilization Embryo Transf 3(5):284–295
Toftager M, Bogstad J, Bryndorf T, Lossl K, Roskaer J, Holland T, Praetorius L, Zedeler A, Nilas L, Pinborg A (2016) Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod 31(6):1253–1264. https://doi.org/10.1093/humrep/dew051
Robert J (2009) Guidance for industry non-inferiority clinical trials. Food and Drug Administration, US Department of Health and Human Services Publishing online. https://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/ucm187447.pdf. Accessed 31 July 2018
Althunian TA, de Boer A, Groenwold RHH, Klungel OH (2017) Defining the noninferiority margin and analysing noninferiority: an overview. Br J Clin Pharmacol 83(8):1636–1642. https://doi.org/10.1111/bcp.13280
Hahn S (2012) Understanding noninferiority trials. Korean. J Pediatr 55(11):403–407. https://doi.org/10.3345/kjp.2012.55.11.403
Zhu X, Zhang X, Fu Y (2015) Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore) 94(21):e909. https://doi.org/10.1097/MD.0000000000000909
Messinis IE (2006) Ovarian feedback, mechanism of action and possible clinical implications. Hum Reprod Update 12(5):557–571. https://doi.org/10.1093/humupd/dml020
Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ (1984) Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab 58(2):378–383. https://doi.org/10.1210/jcem-58-2-378
Harris TG, Dye S, Robinson JE, Skinner DC, Evans NP (1999) Progesterone can block transmission of the estradiol-induced signal for luteinizing hormone surge generation during a specific period of time immediately after activation of the gonadotropin-releasing hormone surge-generating system. Endocrinology 140(2):827–834. https://doi.org/10.1210/endo.140.2.6490
Richter TA, Robinson JE, Evans NP (2002) Progesterone blocks the estradiol-stimulated luteinizing hormone surge by disrupting activation in response to a stimulatory estradiol signal in the ewe. Biol Reprod 67(1):119–125
Richter TA, Robinson JE, Lozano JM, Evans NP (2005) Progesterone can block the preovulatory gonadotropin-releasing hormone/luteinising hormone surge in the ewe by a direct inhibitory action on oestradiol-responsive cells within the hypothalamus. J Neuroendocrinol 17(3):161–169. https://doi.org/10.1111/j.1365-2826.2005.01287.x
Pohl CR, Richardson DW, Marshall G, Knobil E (1982) Mode of action of progesterone in the blockade of gonadotropin surges in the rhesus monkey. Endocrinology 110(4):1454–1455. https://doi.org/10.1210/endo-110-4-1454
Dierschke DJ, Yamaji T, Karsch FJ, Weick RF, Weiss G, Knobil E (1973) Blockade by progesterone of estrogen-induced LH and FSH release in the rhesus monkey. Endocrinology 92(5):1496–1501. https://doi.org/10.1210/endo-92-5-1496
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (2003) Classification and pharmacology of progestins. Maturitas 46(Suppl 1):S7–S16
Schindler AE (2016) Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders: an outlook. Horm Mol Biol Clin Investig 27(2):49–53. https://doi.org/10.1515/hmbci-2016-0028
Tournaye H, Sukhikh GT, Kahler E, Griesinger G (2017) A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod 32(5):1019–1027. https://doi.org/10.1093/humrep/dex023
Zhu X, Ye H, Fu Y (2017) Use of utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a “freeze all” strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility Steril 107(2):379–386. https://doi.org/10.1016/j.fertnstert.2016.10.030 (e374)
Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, Trabucco E, Venturella R, Vajta G, Rienzi L (2016) Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertility Steril 105(6):1488–1495.e1481. https://doi.org/10.1016/j.fertnstert.2016.03.002
Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L (2012) Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertility Steril 97(6):1316–1320. https://doi.org/10.1016/j.fertnstert.2012.03.015
Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL (1995) Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod 10(7):1658–1666
Imoedemhe DA, Sigue AB, Pacpaco EL, Olazo AB (1991) Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertility Steril 55(2):328–332
Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, Andersen CY (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20(5):1213–1220. https://doi.org/10.1093/humrep/deh765
Acknowledgements
The authors wish to thank Ms. Mika Matsuoka for data collection, and Ms. Nami Hirayama and Ms. Yumiko Kobayashi for statistical analysis (clinical staff in the Kamiya Ladies Clinic). We also thank Dr. Shigeo Araki (Chief Director of the International Institute of Medical Technology IMT College) and Dr. Daiki Iwami (staff member of the Department of Renal and Genitourinary Surgery, Hokkaido University, Graduate School of Medicine) for proofreading the manuscript, and Dr. Kota Ono (staff member of the Department of Biostatistics, Hokkaido University, Graduate School of Medicine) as a statistical adviser. We thank Ellen Knapp, PhD, and James Cummins, PhD, from Edanz Group (http://www.edanzediting.com/ac) for editing drafts of this manuscript.
Funding
None.
Author information
Authors and Affiliations
Contributions
NI: Protocol development, data analysis, data collection, manuscript writing. MK: Data collection. NO: Data collection. TY: Data collection. EW: Data collection. OM: Data collection. HK: Data collection, protocol development.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in this study were in accordance with the ethical standards of the Kamiya Ladies Clinic and with the 1964 Helsinki declaration and its later amendments or similar ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Iwami, N., Kawamata, M., Ozawa, N. et al. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet 298, 663–671 (2018). https://doi.org/10.1007/s00404-018-4856-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-018-4856-8